Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors

Pathology International

Volumn 50, Issue 3, 2000, Pages 219-223

  Morita, Katsuo ^a   Ono, Yuko ^a   Fukui, Hirokazu ^b   Tomita, Shigeki ^a   Ueda, Yoshihiko ^a   Terano, Akira ^a   Fujimori, Takahiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunohistochemistry; K ras; Ovarian tumors; P53

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYSTADENOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; ONCOGENE K RAS; OVARY ADENOCARCINOMA; OVARY TUMOR; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 0034015746     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2000.01028.x     Document Type: Article

References (30)

1. 1 Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology. DC Armed Forces Institute of Pathology, Washington, 1998; 51-105.
2. 2 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. 3 Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 1988; 319: 525-532.
4. 4 Kohler MF, Kerns Bj M, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol. 1993; 81: 643-650.
5. 5 Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum. Pathol. 1993; 24: 1175-1179.
6. 6 Inoue M, Fujita M, Enomoto T et al. Immunohistochemical analysis of P53 in gynecologic tumors. Am. J. Clin. Pathol. 1994; 102: 665-670.
7. 7 Gallion HH, Pieretti M, DePriest PD, Nagell JR. The molecular basis of ovarian cancer. Cancer 1995; 76(Suppl): 1992-1997.
8. 8 Fujita M, Enomoto T, Inoue M et al. Alteration of p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn. J. Cancer Res. 1994; 85: 1247-1256.
9. 9 Teneriello MG, Ebina M, Linnoila RI et al. p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993; 53: 3103-3108.
10. 10 Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am. J. Pathol. 1991; 139: 777-785.
11. 11 Mandai M, Konishi I, Kuroda H et al. Heterogeneous distribution of K-ras mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum. Pathol. 1998; 29: 34-40.
12. 12 Ichikawa Y, Nishida M, Suzuki H et al. Mutation of K-ras proto-oncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res. 1994; 54: 33-35.
13. 13 Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O, Rice JM. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 1990; 50: 6139-6145.
14. 14 Mandai M, Konishi I, Koshiyama M et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: Correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994; 54: 1825-1830.
15. 15 Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990; 50: 4087-4091.
16. 16 Japan Society of Obstetrics and Gynecology, The Japanese Society of Pathology. The General Rules for Clinical, Pathological Management of Ovarian Tumours, 1st edn. Kanehara, Tokyo, 1990.
17. 17 Ajiki T, Fujimori T, Onoyama H et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996; 38: 426-429.
18. 18 Jiang W, Kahn SM, Guillem JG, Lu SH, Weinstein IB. Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer. Oncogene 1989; 4: 923-928.
19. 19 Fujimori T, Satonaka K, Yamamura-Idei Y, Nagasako K, Maeda S. Non-involvement of ras mutations in flat colorectal adenomas and carcinomas. Int. J. Cancer 1994; 57: 51-55.
20. 20 Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of ras signaling. Cell 1999; 96: 655-665.
21. 21 Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
22. 22 Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-456.
23. 23 Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705-708.
24. 24 Sawan A, Randall B, Angus B et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. J. Pathol. 1992; 168: 23-28.
25. 25 Yamaguchi A, Kurosaka Y, Fushida S et al. Expression of P53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992; 70: 2778-2784.
26. 26 Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of P53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992; 52: 4828-4831.
27. 27 Horio Y, Takahashi T, Kuroishi T et al. Prognostic significance of p53 mutation and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993; 53: 1-4.
28. 28 Ajiki T, Onoyama H, Yamamoto M et al. P53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996; 43: 521-526.
29. 29 Charles J, Elise K, Eddie R. The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: Epidemiologic, pathologic, and molecular aspects. Gynecol. Oncol. 1996; 60: 347-354.
30. 30 Aure JC, Høeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Obstet. Gynecol. 1971; 37: 1-9.